New Antibiotics for Gram-Positive Infections

  • John S. Bradley
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 582)


Staphylococcus Aureus Otitis Medium Neonatal Intensive Care Unit Acute Otitis Medium Parenteral Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abstract 1297 of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Dec 15–18, 2005, Washington DC, USA.Google Scholar
  2. Appelbaum, P.C., Jacobs, M.R. (2005). Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microbiol. Google Scholar
  3. Babinchak, T., Ellis-Grosse, E., Dartois, N., Rose, G.M., Loh E. (2005). The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41Suppl 5:S354–67.PubMedCrossRefGoogle Scholar
  4. Bhavnani, S.M., Owen, J.S., Loutit, J.S., Porter, S.B., Ambrose, P.G. (2004). Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn. Microbiol. Infect. Dis. 50(2):95–102.PubMedCrossRefGoogle Scholar
  5. Bogaert, D., Hermans, P.W., Adrian, P.V., Rumke, H.C., de Groot, R. (2004). Pneumococcal vaccines: an update on current strategies. Vaccine 22(17–18):2209–20.PubMedCrossRefGoogle Scholar
  6. Boggs, A.F., Miller, G.H. (2004). Antibacterial drug discovery: is small pharma the solution? Clin. Microbiol. Infect. 10Suppl 4:32–6.PubMedCrossRefGoogle Scholar
  7. Brady, M.T. (2005). Health care-associated infections in the neonatal intensive care unit. Am. J. Infect. Control 33(5):268–75.PubMedCrossRefGoogle Scholar
  8. Carpenter, C.F., Chambers, H.F. (2004). Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. 38(7):994–1000.PubMedCrossRefGoogle Scholar
  9. Clark, R., Powers, R., White, R., Bloom, B., Sanchez, P., Benjamin, D.K., Jr. (2004). Prevention and treatment of nosocomial sepsis in the NICU. J. Perinatol. 24(7):446–53.PubMedCrossRefGoogle Scholar
  10. Cosgrove, S.E., Carroll, K.C., Perl, T.M. (2004). Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 39(4):539–45.PubMedCrossRefGoogle Scholar
  11. Ellis-Grosse, E.J., Babinchak, T., Dartois, N., Rose, G., Loh, E. (2005). The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41Suppl 5:S341–53.PubMedCrossRefGoogle Scholar
  12. Fogarty, C.M., Patel, T.C., Dunbar, L.M., Leroy, B.P. (2005). Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. BMC Infect. Dis. 5(1):43.PubMedCrossRefGoogle Scholar
  13. Graham, P.L., 3rd. (2002). Staphylococcal and enterococcal infections in the neonatal intensive care unit. Semin. Perinatol. 26(5):322–31.PubMedCrossRefGoogle Scholar
  14. Green, M., Allen, C., Bradley, J., Dashefsky, B., Gilsdorf, J.R., Marcon, M.J., Schultze, G.E., Smith, C., Walter, E., Martin, J.M., Edwards, K.A., Barbadora, K.A., Rumbaugh, R.M., Wald, E.R. (2005). In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States. Antimicrob. Agents Chemother. 49(6):2487–9.PubMedCrossRefGoogle Scholar
  15. Guay, D.R. (2004). Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 24(1):58–68.PubMedCrossRefGoogle Scholar
  16. Hancock, R.E. (2005). Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect. Dis. 5(4):209–18.PubMedCrossRefGoogle Scholar
  17. Hegde, S.S., Reyes, N., Wiens, T., Vanasse, N., Skinner, R., McCullough, J., Kaniga, K., Pace, J., Thomas, R., Shaw, J.P., Obedencio, G., Judice, J.K. (2004). Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48(8):3043–50.PubMedCrossRefGoogle Scholar
  18. Higgins, D.L., Chang, R., Debabov, D.V., Leung, J., Wu, T., Krause, K.M., Sandvik, E., Hubbard, J.M., Kaniga, K., Schmidt, D.E.Jr., Gao, Q., Cass, R.T., Karr, D.E., Benton, B.M., Humphrey, P.P. (2005). Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3):1127–34.PubMedCrossRefGoogle Scholar
  19. Hoban, D.J., Bouchillon, S.K., Johnson, B.M., Johnson, J.L., Dowzicky, M.J. (2004). In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52(3):215–27.CrossRefGoogle Scholar
  20. Holmes, A., Ganner, M., McGuane, S., Pitt, T.L., Cookson, B.D., Kearns, A.M. (2005). Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. J. Clin. Microbiol. 43(5): 2384–90.PubMedCrossRefGoogle Scholar
  21. Issa, N.C., Rouse, M.S., Piper, K.E., Wilson, W.R., Steckelberg, J.M., Patel, R. (2004). In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn. Microbiol. Infect. Dis. 48(1):73–5.PubMedCrossRefGoogle Scholar
  22. Jacobs, M.R. (2004). Streptococcus pneumoniae: epidemiology and patterns of resistance. Am. J. Med. 117Suppl 3A:3S–15S.PubMedGoogle Scholar
  23. Jarvis, W.R. (2004). Controlling healthcare-associated infections: the role of infection control and antimicrobial use practices. Semin. Pediatr. Infect. Dis. 15(1):30–40.PubMedCrossRefGoogle Scholar
  24. Jones, R.N, Deshpande, L.M., Mutnick, A.H., Biedenbach, D.J. (2002). In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50(6):915–32.PubMedCrossRefGoogle Scholar
  25. Jungbluth, G.L, Welshman, I.R., Hopkins, N.K. (2003). Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr. Infect. Dis. J. 22(9 Suppl):S153–7.PubMedGoogle Scholar
  26. Kaplan, S.L. (2005). Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr. Infect. Dis. J. 24(5):457–8.PubMedCrossRefGoogle Scholar
  27. Kaplan, S.L., Afghani, B., Lopez, P., Wu, E., Fleishaker, D., Edge-Padbury, B., Naberhuis-Stehouwer, S., Bruss, J.B. (2003a). Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr. Infect. Dis. J. 22(9 Suppl):S178–85.PubMedGoogle Scholar
  28. Kaplan, S.L., Deville, J.G., Yogev, R., Morfin, M.R., Wu, E., Adler, S., Edge-Padbury, B., Naberhuis-Stehouwer, S., Bruss, J.B., Linezolid pediatric Study Group (2003b). Linezolid versus vancomycin for treatment of resistant Grampositive infections in children. Pediatr. Infect. Dis. J. 22(8):677–86.PubMedGoogle Scholar
  29. King, A., Phillips, I., Kaniga, K. (2004). Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother. 53(5):797–803.PubMedCrossRefGoogle Scholar
  30. Klaassen, C.H., Mouton, J.W. (2005). Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E). Antimicrob. Agents Chemother. 49(4):1271–8.PubMedCrossRefGoogle Scholar
  31. Kosowska, K., Hoellman, D.B., Lin, G., Clark, C., Credito, K., McGhee, P., Dewasse, B., Bozdogan, B., Shapiro, S., Appelbaum, P.C. (2005). Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49(5):1932–42.PubMedCrossRefGoogle Scholar
  32. Kuehnert, M.J., Hill, H.A., Kupronis, B.A., Tokars, J.I., Solomon, S.L., Jernigan, D.B. (2005). Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg. Infect. Dis. 11(6):868–72.PubMedGoogle Scholar
  33. Leighton, A., Gottlieb, A.B., Dorr, M.B., Jabes, D., Mosconi, G., VanSaders, C., Mroszczak, E.J., Campbell, K.C., Kelly, E. (2004). Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48(3):940–5.PubMedCrossRefGoogle Scholar
  34. Livermore, D.M. (2005). Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother.Google Scholar
  35. Lucero, M.G., Dulalia, V.E., Parreno, R.N., Lim-Quianzon, D.M., Nohynek, H., Makela, H., Williams, G. (2004). Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst. Rev. (4):CD004977.Google Scholar
  36. Lundstrom, T.S., Sobel, J.D. (2005). Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infect. Dis. Clin. North Am. 18(3):651–68.CrossRefGoogle Scholar
  37. Meagher, A.K., Ambrose, P.G., Grasela, T.H., Ellis-Grosse, E.J. (2005). The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. 41Suppl 5:S333–40.PubMedCrossRefGoogle Scholar
  38. Meissner, H.C., Townsend, T., Wenman, W., Kaplan, S.L., Morfin, M.R., Edge-Padbury, B., Naberhuis-Stehouwer, S., Bruss, J.B. (2003). Hematologic effects of linezolid in young children. Pediatr. Infect. Dis. J. 22(9 Suppl):S186–92.PubMedGoogle Scholar
  39. Mitchell, L., Tuomanen, E. (2001). Vancomycin-tolerant Streptococcus pneumoniae and its clinical significance. Pediatr. Infect. Dis. J. 20(5):531–3.PubMedGoogle Scholar
  40. Moellering, R.C. (2003). Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138(2):135–42.PubMedGoogle Scholar
  41. Moran, G.J., Amii, R.N., Abrahamian, F.M., Talan, D.A. (2005). Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg. Infect. Dis. 11(6):928–30.PubMedGoogle Scholar
  42. Noskin, G.A. (2005). Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41Suppl 5:S303–14.PubMedCrossRefGoogle Scholar
  43. Pong, A., Bradley, J.S. (2004). Clinical challenges of nosocomial infections caused by antibiotic-resistant pathogens in pediatrics. Semin. Pediatr. Infect. Dis. 15(1):21–9.PubMedCrossRefGoogle Scholar
  44. Posfay-Barbe, K.M., Wald, E.R. (2004). Pneumococcal vaccines: do they prevent infection and how? Curr. Opin. Infect. Dis. 17(3):177–84.PubMedCrossRefGoogle Scholar
  45. Raad, I., Darouiche, R., Vazquez, J., Lentnek, A., Hachem, R., Hanna, H., Goldstein, B., Henkel, T., Seltzer, E. (2005). Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 40(3):374–80.PubMedCrossRefGoogle Scholar
  46. Robert, J., Etienne, J., Bertrand, X. (2005). Methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a retrospective case series from 12 French hospital laboratories, 2000–2003. Clin. Microbiol. Infect. 11(7):585–7.PubMedCrossRefGoogle Scholar
  47. Roos, K., Tellier, G., Baz, M., Leroy, B., Rangaraju, M. (2005). Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis. J. Infect. 50(3):210–20.PubMedCrossRefGoogle Scholar
  48. Ruef, C. (2004). Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32(6):315–27.PubMedCrossRefGoogle Scholar
  49. Saez-Llorens, X., McCoig, C., Feris, J.M., Vargas, S.L., Klugman, K.P., Hussey G.D., Frenck, R.W., Falleiros-Carvalho, L.H., Arguideas, A.G., Bradley, J., Arrieta, A.C., Wald, E.R., Pancorbo, S., McCracken, G.H. Jr., Marques, S.R., Trovan meningitis Study Group. (2002). Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr. Infect. Dis. J. 21(1):14–22.PubMedGoogle Scholar
  50. Saez-Llorens, X., Rodriguez, A., Arguedas, A., Hamed, K.A., Yang, J., Pierce, P., Echols, R. (2005). Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children. Pediatr. Infect. Dis. J. 24(4):293–300.PubMedCrossRefGoogle Scholar
  51. Saiman, L. (2002). Risk factors for hospital-acquired infections in the neonatal intensive care unit. Semin. Perinatol. 26(5):315–21.PubMedCrossRefGoogle Scholar
  52. Schmitt-Hoffmann, A., Nyman, L., Roos, B., Schleimer, M., Sauer, J., Nashed, N., Brown, T., Man, A., Weidekamm, E. (2004). Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48(7):2576–80.PubMedCrossRefGoogle Scholar
  53. Seltzer, E., Dorr, M.B., Goldstein, B.P., Perry, M., Dowell, J.A., Henkel, T. (2003). Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37(10):1298–303.PubMedCrossRefGoogle Scholar
  54. Shaw, J.P., Seroogy, J., Kaniga, K., Higgins, D.L., Kitt, M., Barriere, S. (2005). Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49(1):195–201.PubMedCrossRefGoogle Scholar
  55. Sher, L., Arguedas, A., Husseman, M., Pichichero, M., Hamed, K.A., Biswas, D., Pierce, P., Echols, R. (2005). Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. Pediatr. Infect. Dis. J. 24(4):301–8.PubMedCrossRefGoogle Scholar
  56. Shi, J., Montay, G., Bhargava, V.O. (2005). Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin. Pharmacokinet. 44(9):915–34.PubMedCrossRefGoogle Scholar
  57. Silverman, J.A., Mortin, L.I., Vanpraagh, A.D., Li, T., Alder, J. (2005). Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191(12):2149–52.PubMedCrossRefGoogle Scholar
  58. Soley, C., Arguedas, A., Porras, W., Guevara, S., Loaiza, C., Perez, A., Rincon, G., Schultz, M., Arguedas, J., Brilla, R. (2005). In vitro activities of levofloxacin and comparable agents against middle ear fluid, nasopharyngeal, and oropharyngeal pathogens obtained from Costa Rican children with recurrent otitis media or failing other antibiotic therapy. Antimicrob. Agents Chemother. 49(7):3056–8.PubMedCrossRefGoogle Scholar
  59. Stein, G.E. (2005). Safety of newer parenteral antibiotics. Clin. Infect. Dis. 41Suppl 5:S293–302.PubMedCrossRefGoogle Scholar
  60. Streit, J.M., Sader, H.S., Fritsche, T.R., Jones, R.N. (2005). Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis. Google Scholar
  61. Stryjewski, M.E., O’Riordan, W.D., Lau, W.K., Pien, F.D., Dunbar, L.M., Vallee, M., Fowler, V.G.Jr., Chu, V.H., Spencer, E., Barriere, S.L., Kitt, M.M., Cabell, C.H., Corey, G.R., FAST Investigator Group. (2005). Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. 40(11):1601–7.PubMedCrossRefGoogle Scholar
  62. Syrogiannopoulos, G.A., Grivea, I.N., Fitoussi, F., Doit, C., Katopodis, G.D., Bingen, E., Beratis, N.G. (2001). High prevalence of erythromycin resistance of Streptococcus pyogenes in Greek children. Pediatr. Infect. Dis. J. 20(9):863–8.PubMedCrossRefGoogle Scholar
  63. Tan, T.Q. (2004). Update on the use of linezolid: a pediatric perspective. Pediatr. Infect. Dis. J. 23(10):955–6.PubMedGoogle Scholar
  64. Tedesco, K.L., Rybak, M.J. (2004). Daptomycin. Pharmacotherapy 24(1):41–57.PubMedCrossRefGoogle Scholar
  65. Weisman, L.E. (2004). Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient. Curr. Opin. Infect. Dis. 17(3):237–41.PubMedCrossRefGoogle Scholar
  66. Wellington, K., Noble, S. (2004). Telithromycin. Drugs 64(15):1683–94; discussion 1695–6.PubMedCrossRefGoogle Scholar
  67. Woodford, N. (2005). Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clin. Microbiol. Infect. 11Suppl 3:2–21.PubMedCrossRefGoogle Scholar
  68. Yogev, R., Patterson, L.E., Kaplan, S.L., Adler, S., Morfin, M.R., Martin, A., Edge-Padbury, B., Naberhuis-Stehouwer, S., Bruss, J.B. (2003). Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr. Infect. Dis. J. 22(9 Suppl):S172–7.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • John S. Bradley
    • 1
  1. 1.Division of Infectious DiseasesChildren’s HospitalSan DiegoUSA

Personalised recommendations